The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 447.50
Bid: 440.00
Ask: 455.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.409%)
Open: 447.50
High: 447.50
Low: 447.50
Prev. Close: 447.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

French study shows superiority of Tristel Wipes

1 Dec 2015 11:05

RNS Number : 5512H
Tristel PLC
01 December 2015
 

 

Tristel plc

("Tristel" or "the Company")

 

French study shows superiority of Tristel Wipes System

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that a French study conducted at a leading university hospital has demonstrated the superiority of its chlorine dioxide wiping method over France's market leader, a peracetic acid soaking method. The methods are alternative ways to disinfect medical instruments used in the Ear, Nose and Throat ("ENT") department of a hospital.

 

The study was undertaken jointly by the infection prevention and ENT departments at the University Hospital, Lille. It focused on the ability of the two disinfectants (Tristel Wipes and Anios Anioxyde 1000) to kill to the requirements of European Standards: a) four different strains of bacteria, and b) a bacterial spore; and the time taken to do so.

 

The Tristel Wipe killed all four bacterial strains in 30 seconds compared to ten minutes for the French product. The Tristel Wipe killed the far more resistant bacterial spore in two minutes, whereas the French product was unable to so in ten minutes. The ability to kill microbes is the most important feature of an instrument disinfectant, but the time taken to do so is almost as important. The duration of the disinfection process is the rate limiting step for an ENT department - the slower it is the fewer the number of patients that can be seen during a clinic.

 

This latest study complements previous published research from the UK, Germany, Italy, New Zealand and Russia that substantiates the benefits of the Tristel Wipes System. During its latest financial year ending 30 June 2015, the Company sold £7.5 million of Wipes worldwide, of which £4.5 million were generated in the UK and £3 million in overseas markets. Tristel has a sales presence in all of the major European countries, but France is its least developed market, and the Company expects this study and other initiatives to accelerate its market penetration there.

 

Paul Swinney, CEO, comments: "We have developed a Wipes business in Germany worth over £1 million in sales, and significant footholds in Spain, Italy, Benelux, and also Scandinavia. Whilst we have a very capable distribution partner in France, the lack of French originated scientific support for our products has held us back in terms of sales. This study is a very positive step forward for us in the French market."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

 

Liz Dixon, Finance Director

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

finnCap

Tel: 020 7600 1658

Geoff Nash/ Giles Rolls (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUGGCUPUPAGGG
Date   Source Headline
8th May 20247:00 amRNSTristel™ ULT case study
7th May 20247:00 amRNSExercise of Share Options and Total Voting Rights
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.